Antonio Cigliola

Featured in: Favicon

onclive.com Favicon

europeanurology.com

Articles

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer | Journal of Clinical Oncology

Sep 6, 2024 | brnw.ch | Marco Moschini |Antonio Cigliola |Valentina Tateo

Data Sharing StatementData Sharing StatementData SupplementAuthors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

Jul 17, 2024 | onclive.com | Antonio Cigliola

CommentaryVideoJuly 17, 2024Author(s):Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC. Antonio Cigliola, MD, medical oncologist, IRCCS San Raffaele Hospital, discusses potential clinical implications of data from the phase 2 SURE-01 study (NCT05226117), as well as anticipated data from the phase 2 SURE-02 trial (NCT05535218), for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Dr Cigliola on the Background of the SURE-01 Study in MIBC

Jul 17, 2024 | onclive.com | Antonio Cigliola

CommentaryVideoJuly 17, 2024Author(s):Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer. Antonio Cigliola, MD, medical oncologist, IRCCS San Raffaele Hospital, discusses the background and safety findings from the phase 2 SURE-01 study (NCT05226117), which evaluated neoadjuvant sacituzumab govitecan-hziy (Trodelvy) in patients with muscle-invasive bladder cancer (MIBC).
Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

Jun 26, 2024 | onclive.com | Antonio Cigliola

Antonio Cigliola, MD, medical oncologist, IRCCS San Raffaele Hospital, discusses interim efficacy findings from the phase 2 SURE-01 study (NCT05226117) investigating neoadjuvant sacituzumab govitecan-hziy (Trodelvy) in patients with muscle-invasive bladder cancer (MIBC). Of the 38 patients who were enrolled onto SURE-01, 31 received neoadjuvant sacituzumab govitecan and 18 completed all 4 cycles of treatment.
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials

Dec 11, 2023 | europeanurology.com | Antonio Cigliola |Valentina Tateo |Carlo Bosi |Alberto Briganti

Vale CL, Fisher DJ, Godolphin PJ, et al. Lancet Oncol 2023;24:783–97The meta-analysis by Vale and colleagues reports the effects of docetaxel added to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) according to patient characteristics. The authors proved that docetaxel prolongs overall survival (OS) in patients with poorer prognosis (high-volume [HV] disease and “bulky” T4 stage tumor).